New details from court documents reveal that at least two other Banks, UK-based Royal Bank of Scotland (RBS) and Switzerland’s UBS AG- played a central role in rigging global benchmark interest rates.
Most of the attention of the LIBOR scandal has focused on trading activities at Barclays, which only last month reached a settlement of $453 million with U.S and UK antitrust authorities for its role in the manipulation of rates. The scandal, which came into light in 2008, brings to light the concerns of rate manipulation especially in the cost of borrowing, home loans and credit card rates.
With the spread of dollar and euro rate rigging since 2005 globally, traders such as Barclays were heavily involved in rate manipulation with big global banks. By 2007, RBS and UBS sought to also influence yen rate markets in order to create favorable trading positions for themselves, sources say. RBS and UBS traders are currently under heavy scrutiny and a focus of much investigation for there alleged involvement in seeking to influence yen dominated rates.
Full content: Reuters
Related content: Why and How Should the Libor Be Reformed? Libor Litigation and the Role of Screening: The Need for Enhanced Compliance Programs
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Anthropic Ordered to Respond After AI Allegedly Fabricates Citation in Legal Filing
May 14, 2025 by
CPI
Rumble Adds David Boies to Legal Team in $2 Billion Antitrust Battle with Google
May 14, 2025 by
CPI
China Summons Delivery Giants Over Unfair Competition Concerns
May 13, 2025 by
CPI
Judge Orders Sanctions Against Missouri for Noncompliance in Price-Fixing Probe
May 13, 2025 by
CPI
Confusion Reigns In AI Policy In US and Europe
May 13, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas